In a retrospective, multicentre study, patients treated with nivolumab or pembrolizumab had a 0.5% prevalence of hypophysitis, with symptoms onset later than those treated with ipilimumab (a median of 26 weeks of treatment, wherein PD-1 inhibitors are typically dosed every 2–6 weeks, depending on the agent and dose). Here, PDCD1 is linked to hypophysitis.